Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses

This article has no abstract
Epistemonikos ID: b88082eafeef42c40f7e18089e6c7f5bb4c888ca
First added on: Feb 08, 2025